Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. Alternatively, you can select "I don't accept" if you wish to leave the website.

Sage Therapeutics

Key Facts as at 30.06.2022

Company locationUSA
Size in % of securities3.20%
Size of stake in company5.00%
Market capitalizationUSD 2.0 bn

Sector

Neurology

Main candidate

Zuranolone

Main indications

Post-partum depression (PPD), Major depressive disorder (MDD), essential tremor (ET), Parkinson’s disease

About the company

Sage Therapeutics is a biotechnology company focused on developing treatments for central nervous system disorders (CNS) utilizing their GABA-A receptor-targeted proprietary platform. Sage was founded in 2010 and is headquartered in Massachusetts in the US. The company is pursuing new pathways with the goal of improving brain health and Sage´s franchise in CNS aims to change how brain disorders are thought about and treated. Sage focuses its research and development on modulation of GABA and NMDA receptors – two critical neurotransmitter systems. The company´s lead therapy, Zulresso, was approved in 2019 for the treatment of post-partum depression. Zulresso has shown rapid and durable efficacy, which sets it apart for all classes of drugs currently used in the field of depression and mood disorders. Sage is developing an oral follow-on version of Zulresso, called zuranolone, which is being evaluated in multiple Phase III trials. Sage has a pipeline of diverse neurology and neuropsychiatry product candidates in earlier development phases including Sage-324 for essential tremor, epilepsy and Parkinson´s disease and Sage-718 for cognitive disorders and Huntington´s disease. The zuranolone franchise and SAGE-324 are both being co-developed with Biogen in a joint venture partnership.

Disclaimer

All comments as at December 31, 2021 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.